Item 8.01. Other Events.



On November 30, 2021, BeiGene, Ltd. (the "Company" or "BeiGene") issued a press
release announcing the pricing of its initial public offering on the Science and
Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange
in China. A copy of this press release is attached hereto as Exhibit 99.1, and
is incorporated herein by reference.

On December 2, 2021, the Company issued a press release announcing that the
China National Medical Products Administration (NMPA) has approved SYLVANT®
(siltuximab for injection) for the treatment of adult patients with multicentric
Castleman disease (MCD) who are human immunodeficiency virus (HIV) negative and
human herpes virus-8 (HHV-8) negative, also known as idiopathic MCD (iMCD). A
copy of this press release is attached hereto as Exhibit 99.2, and is
incorporated herein by reference.

On December 2, 2021, the Company issued a press release announcing that three of
its medicines have been added to the most recent National Reimbursement Drug
List ("NRDL") in China by the National Healthcare Security Administration.
BeiGene-discovered medicines in the updated NRDL include: anti-PD-1 antibody
tislelizumab in three new indications, including in lung and liver cancers; BTK
inhibitor BRUKINSA® (zanubrutinib) in one new indication; and the initial
listing for PARP inhibitor pamiparib. The changes to the NRDL will be effective
on January 1, 2022. A copy of this press release is attached hereto as Exhibit
99.3, and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits.

   Exhibit No.            Description

       99.1               Press Release titled "BeiGene Announces Pricing of its RMB22.2 billion
                          (US$3.5 billion) Initial Public Offering on the

STAR Market of the Shanghai

Stock Exchange in China", issued by BeiGene, Ltd.

on November 30, 2021.



       99.2               Press Release titled "BeiGene and EUSA Pharma

Announce NMPA Approval of


                          SYLVANT® (Siltuximab for Injection) in China for Idiopathic Multicentric
                          Castleman Disease", issued by BeiGene, Ltd. on December 2, 2021.

       99.3               Press Release titled "BeiGene Announces Inclusion in the China National
                          Reimbursement Drug List (NRDL) of Tislelizumab in Three New Indications,
                          BRUKINSA® (zanubrutinib) in One New Indication,

and the First Listing for


                          Pamiparib", issued by BeiGene, Ltd. on December

2, 2021.


       104                The cover page from this Current Report on Form

8-K, formatted in Inline


                          XBRL

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses